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ABSTRACT
It has been several years since the discovery of the pleiotropic effects of vitamin D, and there is still hot 
debate as to the role of vitamin D and attempts to standardise methods of determining 25(OH)D con-
centrations as well as supplementation with vitamin D. Many studies, both observational and randomised 
controlled trials, have revealed a whole range of opportunities of active vitamin D metabolite contribution 
to the treatment of common diseases. A relationship between high concentrations of vitamin D and a low 
risk of incidence of colorectal cancer, cardiovascular diseases, hypertension, ischaemic stroke, depression, 
metabolic syndrome and type 2 diabetes has been suggested for a long time, although recently published 
meta-analyses have created some doubts. There is no consensus regarding vitamin D supplementation 
and the optimum concentration of serum 25(OH)D. The Institute of Medicine’s 2011 report recommends 
achieving serum 25(OH)D concentration of 20 ng/mL as optimal, at a dosage of 600 IU of vitamin D per day. 
International recommendations suggest for individuals at risk a dosage of vitamin D of 2,000 IU per day. 
Polish experts advise that the optimal concentration of 25(OH)D should be greater than 30 ng/mL for adults.
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Introduction
Numerous studies in recent years, related to the 
discovery of the ‘nonclassical’ effects of vitamin D, 
have resulted in immense interest in the possibility of 
multidirectional use of vitamin D measurement in the 
diagnosis and monitoring of the treatment of many 
common diseases. There are several illnesses such as 
Parkinson’s disease, multiple sclerosis, some forms of 
cancers, rheumatoid arthritis, allergic asthma, diabetes 
and heart diseases, in which vitamin D deficiency can 
be identified [1].
Vitamin D status can be defined using static and 
dynamic parameters. The first group includes mea-
surement of blood 25(OH)D concentration, which 
gives information on the amount of substrate available 
to form a biologically active metabolite- 1,25(OH)2D 
(1, 25-dihydroxyvitamin–calcitriol). The dynamic status 
of vitamin D is assessed by concentration of parathyroid 
hormone, bone turnover markers, optimisation of bone 
mass and muscle strength [2]. 
Standardisation of 25(OH)D assays
Reliable measurement of serum 25(OH)D can 
present some difficulties. The first problem is called 
the ‘matrix effect’. It is connected with the structure 
of 25(OH)D, characterised by high hydrophobicity, 
which can result in interference with serum compo-
nents. Another difficulty is the presence of vitamin D 
metabolites which differ in biological activity and affinity 
for liver enzymes, binding proteins and VDR (vitamin D 
receptor). The problem of reliably measuring 25(OH)D 
concentration also results from the presence of 3-epi-
25(OH)D3 stereoisomer, especially in the samples from 
children [2, 3]. According to the current guidelines 
for manufacturers of diagnostic laboratory products, 
there is a need for simultaneous determination of both 
25(OH) D2 and 25(OH) D3 concentrations in the blood. 
It is worth remembering that in some diseases, such as 
renal failure, it is recommended to define both forms of 
vitamin D, i.e. 25 (OH) D and 1,25-dihydroxyvitamin D, 
as the latter is formed in the kidneys. In tuberculosis 
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or sarcoidosis, the opposite situation occurs, namely 
excessive hydroxylation of 25(OH)D in macrophages 
and granulomas leads to an intense increase of calcitriol 
concentration, which can lead to hypercalcaemia [4]. 
The ‘gold standard’ of 25(OH)D determination are 
direct methods such as high performance liquid chro-
matography (HPLC) and tandem mass spectrometry 
coupled with liquid chromatography (LC-MS/MS) allow-
ing at least separate measurements of metabolites such 
as 25(OH)D2, 25(OH)D3 and 3-epi-25(OH)D3. Chemi-
luminescence is the main method used in automatic 
platforms where specific antibodies or labelled proteins 
bind vitamin D molecules [3].
Different methods used for the determination of 
vitamin D (and its metabolites) sometimes produce 
inconsistent results from the same patient specimen. 
These differences in test results can misclassify pa-
tients as having a sufficient or an insufficient vitamin 
D level. In order to standardise vitamin D assays and 
thus ensure the safety of patients’ health, in 2010 the 
National Institutes of Health Office of Dietary Supple-
ments (NIHODS) established the VDSP (Vitamin D 
Standardisation Programme). Within the framework 
of standardisation, 25 experts from various fields rec-
ommended assays which determine concentration of 
25(OH)D2 and 25(OH)D3.
 One of the main problems which affect the quality 
of vitamin D assays is the reference material used to set 
the calibration curve. In vitro diagnostic manufacturers 
use their own reference material, which may result in 
significant differences in outcomes. In order to minimise 
differences in results and unify assay methods, there is 
a need for comparable reference material which could 
help standardise methods and harmonise results ob-
tained from different laboratories [1]. A standardisation 
programme for analysing hormones — HOST (Hormone 
Standardisation Programme) recently qualified vitamin 
D as another hormone. In the first phase of the HOST 
programme, 40 selected native patient samples were 
analysed using the ‘gold standard’, which in this case 
is LC-MS/MS. Using the outcomes, manufacturers were 
obliged to correct their internal reference materials. In 
the absence of a standard, manufacturers are required 
to use reference material prepared by NIST (National 
Institute for Standards and Technology). An additional 
means of helping to unify results of vitamin D assays 
is an external quality control programme DEQAS (The 
International External Quality Assessment Scheme for 
Vitamin D Metabolites) available in Europe. Researchers 
from NIST work to create reference material which could 
help to improve the precision of vitamin D assays from 
different manufacturers.
Laboratories which perform vitamin D assays should 
participate in quality control programmes such as the 
Vitamin D Metabolities Quality Assurance Programme 
(VitDQAP), the College of American Pathologists (CAP), 
or in Europe — DEQAS. These programmes are an 
excellent help in assessing the improvement of quality 
of measurement of 25(OH)D and its metabolites [1].
Supplementation with vitamin D
Reliable and reproducible measurements of serum 
25(OH)D gain an extra dimension in view of the par-
allel incorporation of vitamin D into standard therapy 
of such diseases as atopic dermatitis, multiple scle-
rosis, epilepsy, osteoporosis, kidney failure as well as 
infectious diseases. Recent reports have shown that 
vitamin D supplementation supports basic therapy in 
the treatment of tuberculosis, influenza and infections 
of the upper and lower airways.
It has been observed that patients suffering from 
hepatitis C display a significant decrease in serum 
25(OH)D levels, below 20 ng/mL. In the study by Lange, 
a beneficial influence of calcitriol administration has 
been suggested, which has the effect of amplifying 
standard HCV therapy [5, 6]. Leis et al. documented 
that children under five years of age, whose daily intake 
of vitamin D does not exceed 80 IU/kg, were charac-
terised by a four-fold greater degree of incidence of 
diseases associated with acute lower respiratory tract 
infections. Leis’s studies suggest that optimal supple-
mentation with vitamin D could prevent bronchiolitis 
and pneumonia [5, 7]. 
A Polish intervention study on patients with atopic 
dermatitis who had received treatment with vitamin 
D supplementation in an amount of 2,000 IU/daily 
for three months (in patients with vitamin D deficien-
cy < 20 ng/mL), revealed a two-fold increase in serum 
25(OH)D levels, accompanied by a two-fold decrease 
in symptoms of atopic dermatitis [8]. Uncontrolled 
observational studies conducted by Pierrot-Deseilligny 
concerned the impact of vitamin D supplementation, 
used in parallel with primary therapy, on remission 
and relapses of multiple sclerosis. It was observed that 
the rate of recurrence of multiple sclerosis decreased 
(13.7%) with increasing concentration of 25(OH)D for 
every 4 ng/mL (10 nmol/L) [9]. 
Shroff et al. supported the hypothesis concerning 
a positive impact of ergocalciferol (vitamin D2) sup-
plementation in chronic renal failure. Supplementing 
vitamin D2 delayed the development of secondary hy-
perparathyroidism in children in the 2nd and 3rd stages 
of chronic renal failure [10]. The study by Alvarez et al. 
suggested an impact of cholecalciferol (vitamin D3) on 
reduction of PTH at the early stage of chronic renal fail-
ure in adults [11]. Carmel et al. referred to a relationship 
between the effects of bisphosphonate therapy and the 
concentration of 25(OH)D. Bisphosphonates are widely 
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used in the treatment of patients with osteoporosis. They 
found a strong relationship between the long-term re-
sponse of patients treated with bisphosphonates and 
optimal (≥ 33 ng/mL) concentrations of 25(OH)D [12]. 
Bertodolo et al. stated that 25(OH)D regulated the first 
stage of bisphosphonate therapy in a group of women 
with osteoporosis aged 63.7 ± 10.6 years. Optimisa-
tion of 25(OH)D concentration during bisphosphonate 
therapy led to a decrease in CRP levels and a decrease 
of elevated body temperature [13, 14].
The therapeutic effect of vitamin D supplementation 
has also been observed in patients suffering from de-
pressive disorders. Combination of primary treatment 
and supplementation of vitamin D gave better results in 
the treatment of increasing depressive symptoms. The 
therapeutic effect of vitamin D in the treatment of mental 
disorders and other conditions related to the nervous 
system (epilepsy, multiple sclerosis) is probably due to 
the presence of vitamin D receptors in the cells of the 
nervous system as well as local prohormone hydrox-
ylation to its active form, which is calcitriol. However, 
a detailed explanation of these mechanisms requires 
further studies [5, 15]. 
There are several plausible biological mechanisms 
relating vitamin D to coronary heart failure. The active 
form of vitamin D influences about 3% of the human 
genome [16]. After binding to VDR, calcitriol affects the 
proliferation and apoptosis process. This could result in 
inhibition of vascular smooth muscle cell proliferation, 
which is believed to be a cardioprotective mechanism. 
Another positive role of suboptimal concentration of 
vitamin D is the anti-inflamatory and immune modulating 
effect. Vitamin D affects also the renin-angiotensin-aldo-
sterone system which is perceived by many researchers 
as a possible pathway linking deficiency of 25(OH)D 
and high blood pressure [14, 16]. 
According to scientific reports, a suitable vitamin 
D supplementation to achieve a concentration of se-
rum 25(OH)D in adults of between 30–60 ng/mL may 
be a strengthening factor of therapy effectiveness in 
cases of infectious diseases, osteoporosis, multiple 
sclerosis, epilepsy, chronic renal failure and atopic 
dermatitis [5,17]. 
Relationship of vitamin D status and 
inflammation 
Concentration of 25(OH)D significantly decreases 
during the acute phase of many diseases which are 
accompanied by multi-organ failure and extensive 
inflammation. A similar drastic decrease in serum 
25(OH)D is observed in patients undergoing knee 
replacement, in patients with acute pancreatitis, 
congestive heart failure or myocardial infarction; all 
these disorders are also accompanied by an extensive 
inflammatory process. In many diseases, particularly 
during the acute phase, which is characterised by 
a high extent of ongoing inflammatory processes, an 
inverse relationship between serum 25(OH)D level and 
inflammatory markers levels, such as TNF and CRP, 
has been observed. Therefore, recently scientists have 
formed a hypothesis linking the decrease of serum 
25(OH) D, accompanying multiple diseases, with 
ongoing inflammatory process [17].
Vitamin D in recent systematic reviews  
and meta-analyses
There are discrepancies between observational 
and interventional studies concerning the relationship 
between serum 25(OH)D and the risk of cancer devel-
opment, except colorectal cancer [17]. There are many 
prospective studies revealing an inverse relationship 
between serum 25(OH)D and cardiovascular diseases, 
serum lipid levels, weight gain, infectious diseases, 
mental disorders and cognitive decline. On the other 
hand, there are studies that suggest slight or no effect 
of therapeutic use of vitamin D in a number of illness-
es. The insignificant effect of vitamin D supplementation 
in the development and severity of many diseases may 
suggest a hypothesis that lowering serum concentration 
of 25(OH)D could be the result, but not the cause, of 
‘ill health’ [17].
This hypothesis assumes that the decrease in vi-
tamin D concentration could be a biological marker of 
deteriorating health in response to the development of 
a specific disease. Some observational studies confirm 
this hypothesis. An example is a Dutch cohort study, 
conducted on a large group of older people, among 
whom overall survival was gradually decreased with the 
decrease of 25(OH)D in the serum [17, 18].
Many cardiovascular diseases such as coronary 
heart disease, sudden cardiac death, peripheral arterial 
disease and greater carotid intima-media thickness are 
accompanied by low vitamin D concentration in the 
serum [14, 19]. A growing body of evidence indicates 
a moderate association between vitamin D concentra-
tion and the risk of death from coronary heart disease, 
cancer, lymphoma or respiratory diseases [16]. Al-
though evidence from observational studies reveals an 
association between 25(OH)D and the risk of develop-
ment of cardiovascular disease, cancer or a non-cancer 
disease, most studies with vitamin D supplementation 
have not demonstrated a positive effect on CVD. The 
lack of strong evidence may be the result of inadequate 
supplementation of vitamin D, and trials with higher 
vitamin D doses are essential for a final explanation of 
the effect of vitamin D on cardiovascular events [14]. 
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In their recent systematic review and meta-analysis 
of observational cohort and randomised intervention 
studies, Chowdhury et al. indicated the inverse asso-
ciation of serum vitamin D concentration with risks of 
death from cardiovascular diseases, cancer and other 
causes and beneficial effect of vitamin D supplementa-
tion. Interestingly, they found that supplementation with 
vitamin D3 given alone reduced mortality significantly 
(by 11%) whereas vitamin D2 given alone had no effect 
on overall mortality [20]. 
The restoration of optimal serum 25(OH)D levels 
may provide an important therapeutic help during the 
treatment of many diseases. However, a very recent 
controversial report by Theodoratou et al. reveals that 
there is in fact no evidence which supports the argument 
that vitamin D-only supplementation increases bone 
mineral density or reduces the risk of fractures or falls 
in the elderly [20]. 
The authors indicate the possible associations 
of vitamin D only with some outcomes such as birth 
weight, dental caries in children and PTH concentrations 
in patients with chronic kidney disease. Finally, they 
state that low doses and short duration of vitamin D 
supplementation in the randomised controlled trials 
may be the reason for there not being enough evidence 
to draw conclusions [20]. On the other hand, Li et al. 
very recently published a systematic review and me-
ta-analysis on the impact of vitamin D status on cancer 
patients’ outcomes. This meta-analysis, involving more 
than 17,000 patients suffering from different forms of 
cancer, once again emphasised the contribution of high 
doses of vitamin D in remission and overall survival. The 
evidence from studies by Li seems to confirm that only 
high doses of vitamin D allow the exertion of a protec-
tive effect against cancer, particularly breast cancer, 
colorectal cancer, and lymphoma. 
There are hypotheses confirmed by many studies 
which suggest that the protective effect of vitamin D on 
cancer is a consequence of the inhibition in the growth 
of tumours and modulation of the microenvironment 
in which tumour cells are located. Patients suffering 
from colorectal cancer, lymphoma or breast cancer 
with concentration of vitamin D in the highest quartile 
presented significantly better overall survival. Investiga-
tors have estimated that an increase in concentration 
of circulating 25(OH)D, by 4ng/mL (10 nmol/L) can 
reduce all-cause mortality by 4% among patients with 
cancer. In addition to the positive effects of vitamin D 
treatment of cancer, it may also alleviate adverse 
reactions caused by primary treatment. In the study 
by Li, a relationship has been observed between low 
levels of 25(OH)D among men with a high and a very 
high risk of developing prostate cancer according to 
the National Comprehensive Cancer Network (NCCN) 
criteria. Moreover, vitamin D deficiency could be a good 
predictor in the diagnosis of more aggressive forms 
of prostate cancer and supplementation may prevent 
prostate cancer incidence or even inhibit tumour pro-
gression [21, 22].
Current recommendations
International organisations recommend in general 
800–1,000 IU/day of vitamin D to achieve optimal 
25(OH)D concentration for adults, although for individ-
uals at higher risk the doses may be up to 2,000 IU/day 
[14]. The Endocrine Society in the US points out that 
doses of 1,500-2,000 IU/day may be required for all 
adults to raise 25(OH)D concentration to > 30 ng/mL 
(optimal for adults between 30–60 ng/mL). Similarly, ac-
cording to recent Polish recommendations, the optimal 
level of serum 25(OH)D in adults is > 30 ng/mL [23].
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